Lineage, Inc. Common Stock (LINE)vsUnum Group 6.250% JR NT58 (UNMA)
LINE
Lineage, Inc. Common Stock
$37.75
+0.96%
REAL ESTATE · Cap: $9.50B
UNMA
Unum Group 6.250% JR NT58
$21.45
+0.42%
REAL ESTATE · Cap: $5.35B
Smart Verdict
WallStSmart Research — data-driven comparison
UNMA leads profitability with a 0.0% profit margin vs -3.1%. LINE earns a higher WallStSmart Score of 35/100 (F).
LINE
Avoid35
out of 100
Grade: F
UNMA
Avoid20
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Areas to Watch
0.8% revenue growth
0.0% earnings growth
Operating margin of 3.7%
Elevated debt levels
0.0% revenue growth
0.0% earnings growth
ROE of 7.2% — below average capital efficiency
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : UNMA
The strongest argument for UNMA centers on P/E Ratio.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : UNMA
The primary concerns for UNMA are Revenue Growth, EPS Growth, Return on Equity.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while UNMA is a value play — different risk/reward profiles.
LINE is growing revenue faster at 0.8% — sustainability is the question.
UNMA generates stronger free cash flow (474M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LINE scores higher overall (35/100 vs 20/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.
Visit Website →Unum Group 6.250% JR NT58
REAL ESTATE · REIT - RESIDENTIAL · USA
Unum Group offers financial protection benefits solutions in the United States, the United Kingdom, and internationally. The company is headquartered in Chattanooga, Tennessee.
Visit Website →Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?